Last updated: February 16, 2026
Market Analysis and Price Projections for NDC 43598-0349
Overview of the Drug
NDC 43598-0349 is identified as Ruzurgi (amifampridine), a medication approved by the FDA for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients aged 6 to 17. Launched in 2019, Ruzurgi is marketed by Jacobus Pharmaceutical.
Market Landscape
Indication and Patient Demographics
- Target Population: Pediatric and adolescent patients with LEMS.
- Prevalence: Estimated at approximately 3 cases per million, with the pediatric subset being smaller.
- Current Treatment Options: Limited; Ruzurgi is the only FDA-approved drug for this age group.
Competitive Environment
- Market Exclusivity: Patent protection was granted until 2035.
- Off-Label Use: No significant off-label competition due to rarity of the disease and pediatric indication.
- Market Access: Coverage largely depends on payer policies, with rare disease designations facilitating access.
Sales Data (2022-2023)
- Sales volumes remain low, approximating $10 million annually in the U.S.
- Market penetration is restricted by the rarity of LEMS and pediatric approval scope.
Price Analysis
Current Pricing
- Average Wholesale Price (AWP): Approximately $4,500 to $5,000 per 30-day supply.
- List Price: Consistent with other rare disease drugs, around $150,000 to $180,000 annually.
Reimbursement Dynamics
- Insurance Coverage: Generally favorable due to FDA approval and orphan status.
- Patient Assistance Programs: Available, reducing out-of-pocket expenses for eligible patients.
Price Projection Factors
Market Growth Drivers
- Increased diagnosis awareness may expand the treated population minimally.
- Potential for label expansion to include adult use, which could significantly augment the market.
- Orphan drug incentives provide a stable pricing environment.
Pricing Outlook (2024-2028)
| Year |
Estimated Average Price (per year) |
Notes |
| 2024 |
$180,000 |
Stable, barring policy changes |
| 2025 |
$180,000 |
No substantial price pressure |
| 2026 |
$185,000 |
Adjustment for inflation |
| 2027 |
$190,000 |
Possible label expansion |
| 2028 |
$195,000 |
Continued inflation |
Risks Impacting Price and Market
- Regulatory delays in label expansion.
- Emergence of competing therapies or biosimilars.
- Pricing pressure from payers due to healthcare cost containment.
Key Takeaways
- NDC 43598-0349 (Ruzurgi) controls a niche but stable market with limited current growth.
- The drug's pricing has remained consistent, reflecting rarity, patent protection until 2035, and market exclusivity.
- Significant upside exists if indications expand, but primary growth is limited within the current Pediatric LEMS indication.
- Sales potential hinges on diagnosis awareness, payer acceptance, and eventual label modifications.
FAQs
1. What is the primary driver for Ruzurgi pricing stability?
Patent protection and orphan drug status limit competition, allowing stable, high pricing.
2. How significant is the market for Ruzurgi?
Estimated annual sales are around $10 million in the U.S., based on current patient numbers and pricing.
3. What could influence future price changes?
Label expansion, increased diagnosis, and new competitive entrants would impact pricing.
4. Are there biosimilar or generic options?
No biosimilars or generics are available due to patent protections and the drug’s orphan status.
5. How does payor coverage affect the market?
Most payers cover Ruzurgi due to rare disease designation, facilitating access but with negotiated rebates and coverage limitations.
References
[1] FDA. "Ruzurgi (amifampridine) Approval Letter." 2019.
[2] IQVIA. "Pharmaceutical Market Data, 2022-2023."
[3] Jacobus Pharmaceuticals. "Ruzurgi Product Information."
[4] MarketResearch.com. "Rare Disease Drug Pricing & Market Trends," 2023.
